



**PANGAEA**  
ONCOLOGY



**IOR**

INSTITUTO  
ONCOLÓGICO  
ROSELL



**International  
Breast Cancer  
Center**

# OUR SCIENTIFIC PUBLICATIONS

| REPORT 2022

## OUR SCIENTIFIC PUBLICATIONS | IOR

Rafael Rosell & Peng Cao. “Promising outlook with sugemalimab in non-small-cell lung cancer” **Lancet Oncology** 2022 Published Online January 14, (Vol 23): 186-187, 2022  
[https://doi.org/10.1016/S1470-2045\(21\)00698-7](https://doi.org/10.1016/S1470-2045(21)00698-7) **IF: 41.316**

Rafael Rosell, María González-Cao “Ablating lung cancer, knowing the tumor better” **The Lancet Regional Health - Europe** 2022;22: 100494 <https://doi.org/10.1016/j.lanepe.2022.100494>

Rafael Rosell, Andrés F. Cardona, Oscar Arrieta, María González-Cao “Classification of atypical EGFR mutations in non-small-cell lung cancer” **Ann Oncol** 2022 Mar 21;S0923-7534(22)00389-1. <https://doi.org/10.1016/j.annonc.2022.03.010> VOLUME 33, ISSUE 6, P571-573, JUNE 01, 2022  
**IF: 51.769**

Rafael Rosell, María González-Cao, Masaoki Ito, Mireia Marco Jordan, José Luis Gómez-Vázquez, Jing-Hua Chen, Andrés Aguilar, Imane Chaib. “Kisspeptins and norepinephrine regulate different G-protein-coupled receptor signaling pathways” **Transl Lung Cancer Res** 2022 |  
<https://dx.doi.org/10.21037/tlcr-22-494> **IF: 4.726**

Salvador Guardiola · Macarena Sánchez Navarro · Rafael Rosell · Ernest Giralt · Jordi Codony Servat. “Anti-EGF nanobodies enhance the antitumoral effect of osimertinib and overcome resistance in non-small cell lung cancer (NSCLC) cellular models” **Medical Oncology**, 2022  
<https://doi.org/10.1007/s12032-022-01800-1> **IF: 3.733**

AF Cardona, M González-Cao, O Arrieta and Rafael Rosell. “Location of EGFR exon 20 insertions matters” **Cancer Cell** 2022 <https://doi.org/10.1016/j.ccell.2022.06.002> **IF: 31.743**

Navneet Singh, Sarah Temin, Sherman Baker, ... Rafael Rosell ... et al. “Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Guideline Update”. **J Clin Oncol** 2022, <https://doi.org/10.1200/JCO.22.00824> **IF: 44.544**

Navneet Singh, Sarah Temin, Sherman Baker, ... Rafael Rosell ... et al. “Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Guideline Update”. **J Clin Oncol** 2022, <https://doi.org/10.1200/JCO.22.00825> **IF: 44.544**

R. A. Soo, J.-Y. Han, U. Dafni, B. C. Cho, C. M. Yeo, E. Nadal, E. Carcereny, J. de Castro, M. A. Sala, R. Bernabé, L. Coate, M. Provencio Pulla, R. Garcia Campelo, S. Cuffe, S. M. S. Hashemi, M. Früh, B. Massuti, J. Garcia-Sanchez, M. D. Mine, M. Majem, J.-M. Sanchez-Torres, C. Britschgi, M. Pless, G. Dimopoulou, H. Roschitzki-Voser, B. Ruepp, R. Rosell, R. A. Stahel & S. Peters, on behalf of the ETOP 10-16 BOOSTER Collaborators "A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial" **Ann Oncol** 2022, 33 (2): 181-192. **IF: 51.769** <https://doi.org/10.1016/j.annonc.2021.11.010>

Sjors G.J.G. In't Veld, Mohammad Arkani, Edward Post, Mafalda Antunes-Ferreira, ... Rafael Rosell, ... Myron Best, Thomas Wurdinger "Detection and localization of early- and late-stage cancers using platelet RNA" **Cancer Cell** 2022 <https://doi.org/10.1016/j.ccell.2022.08.006> **IF: 31.743**

Luis E. Raez, Oscar Arrieta, Diego F. Chamorro, Pamela Denisse Soberanis-Piña, Luis Corrales, Claudio Martín, Mauricio Cuello, Suraj Samtani, Gonzalo Recondo, Luis Mas, Zyanya Lucia Zatarain-Barrón, Alejandro Ruíz-Patiño, Juan Esteban García-Robledo, Camila Ordoñez-Reyes, Elvira Jaller, Franco Dickson, Leonardo Rojas, Christian Rolfo, Rafael Rosell, Andrés F. Cardona. "Durvalumab After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: Inferior Outcomes and Lack of Health Equity in Hispanic Patients Treated With PACIFIC Protocol (LA1-CLICaP)" **Front Oncol.** 2022; 12: 904800. Published online 2022 Jul 12. doi: 10.3389/fonc.2022.904800. **IF: 6.244**

Alejandro Ruiz-Patiño, July Rodríguez, Andrés F. Cardona, Jenny Ávila, Pilar Archila, Hernán Carranza, Carlos Vargas, Jorge Otero, Oscar Arrieta, Lucia Zatarain-Barrón, Carolina Sotelo, Camila Ordoñez, Juan Esteban García-Robledo, Leonardo Rojas, Maritza Bermúdez, Tatiana Gámez, Diana Mayorga, Luis Corrales, Claudio Martín, Gonzalo Recondo, Luis Mas, Suraj Samtani, Luisa Ricaurte, Umberto Malapelle, Alessandro Russo, Feliciano Barrón, Nicolas Santoyo, Christian Rolfo, Rafael Rosell, on behalf of ONCOLGroup, CLICaP. "p.G12C KRAS mutation prevalence in non-small cell lung cancer: Contribution from interregional variability and population substructures among Hispanics" **Transl Oncol** 2022 Jan; 15(1): 101276. Published online 2021 Nov 22. doi: 10.1016/j.tranon.2021.101276 **IF: 3.558**

Oscar Arrieta, Zyanya Lucia Zatarain-Barrón, Jenny G. Turcott, Feliciano Barrón, Sai Yendamuri, Andrés F. Cardona, Rafael Rosell. "Association of BMI With Benefit of Metformin Plus Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients With Advanced Lung Adenocarcinoma" **JAMA Oncology** 2022. 8(3):477-479. doi:10.1001/jamaoncol.2021.7015 **IF: 31.777**

Pedro Barrios-Bernal, Norma Hernandez-Pedro, Mario Orozco-Morales, Rubí Viedma-Rodríguez, José Lucio-Lozada, Federico Avila-Moreno, Andrés F. Cardona, Rafael Rosell, Oscar Arrieta "Metformin enhances TKI-afatinib cytotoxic effect, causing downregulation of glycolysis, epithelial-mesenchymal transition, and EGFR-signaling pathway activation in lung cancer cells" **Pharmaceuticals** 2022. Mar 21;15(3):381. doi: 10.3390/ph15030381 **IF: 5.677**

Andrés F Cardona, Alejandro Ruiz Patiño, Gonzalo Recondo, Claudio Martin, Luis Ráez, Suraj Samtani, José Nicolás Minata, Juan Bautista Blaquier,... Christian Rolfo, Lucia Viola, Rafael Rosell, Oscar Arrieta. "Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP)" **Clinical Lung Cancer IN PRESS** 2022 DOI:<https://doi.org/10.1016/j.clc.2022.06.001> **IF: 4.785**

Vladmir C. Cordeiro de Lima, Marcelo Corassa, Erick Saldanha, Helano Freitas, Oscar Arrieta, Luis Ráez, Suraj Samtani, Maritza Ramos, Carlos Rojas, Mauricio Burotto, Diego F. Chamorro, Gonzalo Recondo, Alejandro Ruiz-Patiño Luis Más, Lucia Zatarain-Barrón, Sergio Mejía, José Nicolas Minata, Claudio Martín, Juan Bautista Blaquier, Rodrigo Motta Guerrero, Carlos Aliaga-Macha, Carlos Carracedo, Camila Ordóñez- Reyes, Juan Esteban Garcia-Robledo, Luis Corrales, Carolina Sotelo, Luisa Ricaurte, Nicolas Santoyo, Mauricio Cuello, Elvira Jaller, July Rodríguez, Pilar Archila, Maritza Bermudez, Tatiana Gamez, Alessandro Russo, Lucia Viola, Umberto Malapelle, Diego de Miguel Perez, Christian Rolfo, Rafael Rosell, Andrés F. Cardona "STK11 and KEAP1 mutations in Non-small cell lung cancer patients: descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP)" **Lung Cancer** 170 (2022) 114-121 <https://doi.org/10.1016/j.lungcan.2022.06.010> . **IF: 5.705**

Juan Esteban Garcia-Robledo, Rafael Rosell, Alejandro Ruiz-Patiño, Carolina Sotelo, Oscar Arrieta, Lucia Zatarain-Barrón, Camila Ordoñez, Elvira Jaller, Leonardo Rojas, Alessandro Russo, Diego de Miguel-Pérez, Christian Rolfo, Andrés F. Cardona. "KRAS and MET in Non-small cell lung cancer: two of the new kids on the "drivers" block" **Therapeutic Advances in Respiratory Disease** 2022; 16:17534666211066064. doi: 10.1177/17534666211066064. **IF: 3.723**

D. Rodríguez-Abreu, M. Cobo, S. García-Román, S. Viteri-Ramírez, N. Jordana-Ariza, B. García-Peláez, N. Reguart, A. Aguilar, J. Codony-Servat, A. Drozdowskyj, M.A. Molina- Vila, E. d'Hondt, R. Rosell. "The EPICAL trial, a Phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC". **Lung Cancer**, 164 (2022) 8-13, 2022 <https://doi.org/10.1016/j.lungcan.2021.12.014> **IF: 5.705**

Carlos Pedraz-Valdunciel, Stavros Giannoukakos, Nicolas Potie, Ana Gimenez-Capitán, Chung-Ying Huang, Michael Hackenberg, Alberto Fernández-Hilario, Jillian W.P. Bracht, Martyna Filipaska, Erika Aldeguer, Sonia Rodríguez-Muñoz, Trever Bivona, Sarah Warren, Cristina Aguado-Esteban, Masaoki Ito, Andrés Aguilar-Hernández, Miguel Angel Molina-Vila, Rafael Rosell “Digital multiplexed analysis of circRNAs in FFPE and fresh NSCLC specimen” **MOL ONCOL** 2022 Jan 21. doi: 10.1002/1878-0261.13182. **IF: 6.603**

Carlos Pedraz-Valdunciel, Stavros Giannoukakos, Ana Gimenez-Capitán, Diogo Fortunato, Martyna Filipaska, Jordi Bertran-Alamillo, Jillian W.P. Bracht, Joselyn Valarezo, Natasa Zarovni, Alberto Fernández-Hilario, Michael Hackenberg, Andrés Aguilar-Hernández, Miguel Angel Molina-Vila, Rafael Rosell “Multiplex analysis of circRNAs from plasma extracellular vesicle-enriched samples for the detection of early-stage non-small cell lung cancer” **Pharmaceutics** 2022 doi: 10.3390/pharmaceutics14102034. **IF: 6.321**

Julia Elzanowska, Laura Berrocal, Beatriz García-Peláez, Marta Vives-Usano, Beatriz Passos Sebo, Joana Maia, Silvia Batista, Jaakko Teppo, Markku Varjosalo, Maria Carolina Strano Moraes, Miguel Ángel Molina-Vila, Bruno Costa-Silva. “Defining Optimal Conditions for Tumor Extracellular Vesicle DNA Extraction for Mutation Profiling” **Cancers** (Basel) 2022 Jul; 14(13): 3258. Published online 2022 Jul 2. doi: 10.3390/cancers14133258. **IF: 6.639**

Eduarne Arriola, María González-Cao, Manuel Domine, Javier De Castro, Manuel Cobo, Reyes Bernabé, Alejandro Navarro, Ivana Sullivan, José Manuel Trigo, Joaquín Mosquera, Leonardo Crama, Dolores Isla. “Addition of Immune Checkpoint Inhibitors to Chemotherapy vs Chemotherapy Alone as First-Line Treatment in Extensive-Stage Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis” **Oncol Ther** 2022 Jun; 10(1): 167-184. Published online 2022 Jan 15. doi: 10.1007/s40487-021-00182-0. **IF: 2.160**

Thomas A Odeny, Kathryn Lurain, Julius Strauss, Steven P Fling, Elad Sharon, Anna Wright, Javier Martinez-Picado, Teresa Moran, James L Gulley, Maria Gonzalez-Cao, Thomas S Uldrick, Robert Yarchoan, Ramya Ramaswami. “Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer” **J Immunother Cancer**. 2022; 10(9): e005128. Published online 2022 Sep 2. doi: 10.1136/jitc-2022-005128 **IF: 12.469**

Marta Sisteré-Oró, Naina Andrade, Diana D.J. Wortmann, Juan Du, Natalia Garcia-Giralt, María González-Cao, Robert Güerri-Fernández, Andreas Meyerhans. “Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccination” **Front Immunol**. 2022; 13: 994173. Published online 2022 Aug 26. doi: 10.3389/fimmu.2022.994173. **IF: 7.561**

González-Cao M, Rosell R- “Neoantigen personalized vaccine plus anti- PD-1 antibody in cancer patients” **Pharmacogenomics Research and Personalized Medicine 2022** | <https://dx.doi.org/10.21037/prpm-21-23> . **IF: 3.88**

Marta Sisteré-Oró, Diana DJ Wortmann, Naína Andrade, Andres Aguilar, Clara Mayo De Las Casas, Florencia Garcia Casabal, Susana Torres, Eduardo Bona Salinas, Laura Raventos Soler, Andrea Arcas, Carlos Esparre, Beatriz Garcia, Joselyn Valarezo, Rafael Rosell, Robert Güerri-Fernández, Maria Gonzalez Cao and Andreas Meyerhans “Anti-SARS-CoV-2 immunity in long lasting responders to cancer immunotherapy through mRNA-based COVID-19 vaccination”. **Frontiers in Immunology**, 2022 13: 908108 doi: 10.3389/fimmu.2022.908108 **IF: 7.561**

Kallergi G, Kontopodis E, Ntzifa A, Jordana-Ariza N, Karachaliou N, Pantazaka E, Charalambous HA, Psyri A, Tsaroucha E, Boukovinas I, Koumarianou A, Hatzidaki D, Lianidou E, Georgoulis V, Rosell R, Kotsakis A. “Effect of Osimertinib on CTCs and ctDNA in EGFR Mutant Non-Small Cell Lung Cancer Patients: The Prognostic Relevance of Liquid Biopsy”. **Cancers 2022**. Mar 19;14(6):1574. doi: 10.3390/cancers14061574. **IF: 6.639**

Shigeki Nanjo, Wei Wu, Niki Karachaliou, Collin Blakely, Junji Suzuki, Siraj Ali, Daniel Kerr, Victor Olivas, Jonathan Shue, Julia Rotow, Manasi Mayekar, Franziska Haderk, Nilanjana Chatterjee, Yuriy Kirichok, Daniel Shao-Weng Tan, Rafael Rosell, Ross Okimoto, and Trever Bivona. “Deficiency of the splicing factor RBM10 limits EGFR targeted therapy response in EGFR mutant lung cancer” **J Clin Invest**. 2022;132(13):e145099. <https://doi.org/10.1172/JCI145099> **IF: 14.808**

Leonardo Rojas, Diana Mayorga, July Rodríguez, Andrés F. Cardona, Pilar Archila, Jenny Avila, Melissa Bravo, Luisa Ricaurte, Carolina Sotelo, Oscar Arrieta, Lucia Zatarain-Barrón, Hernán Carranza, Jorge Otero, Carlos Vargas, Feliciano Barrón, Luis Corrales, Claudio Martín, Gonzalo Recondo, Luis Eduardo Pino, Maritza A. Bermudez, Tatiana Gamez, Christian Rolfo, Rafael Rosell; on behalf of CLICaP “Human papillomavirus infection and lung adenocarcinoma. Special benefit is observed in patients treated with immune checkpoint inhibitors”. **ESMO Open Vol 7 (4) 2022** <https://doi.org/10.1016/j.esmoop.2022.100500> **IF: 5.329**

U. Dafni, R. A. Soo, S. Peters, Z. Tsourti, P. Zygoura, K. Vervita, J.-Y. Han, J. De Castro, L. Coate, M. Früh, S. M. S. Hashemi, E. Nadal, E. Carcereny, M. A. Sala, R. Bernabé, M. Provencio, S. Cuffe, H. Roschitzki-Voser, B. Ruepp, R. Rosell & R. A. Stahel. “Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC – A systematic review and meta-analysis” **ESMO Open Vol 7 (3) 2022** <https://doi.org/10.1016/j.esmoop.2022.100507> **IF: 5.329**

Caterina De Luca, Francesco Pepe, Pasquale Pisapia, Antonino Iaccarino, Luisella Righi, Angela Listi, Gianluca Russo, Severo Campione, Fabio Pagni, Mariantonia Nacchio, Floriana Conticelli, Maria Russo, Teresa Fabozzi, Elena Vigliar, Claudio Bellevicine, Danilo Rocco, Stefano Laudati, Giuseppe Iannaci, Bruno Daniele, Cesare Gridelli, Diego Luigi Cortinovis, Silvia Novello, Miguel Angel Molina-Vila, Rafael Rosell, Giancarlo Troncone & Umberto Malapelle. "RNA-Based NGS in Non-Small Cell Lung Cancer in routine setting: an experience from an Italian referral center". **Personalized Medicine** 10.2217/pme-2022-0020 C 2022 **IF: 2.119**

Rita B. Soares, Rita Manguinhas, João G. Costa, Nuno Saraiva, Nuno Gil, Rafael Rosell, Sérgio P. Camões, Ines Batinic-Haberle, Ivan Spasojevic, Matilde Castro, Joana P. Miranda, Filipa Amar Joana Pinto, Ana S. Fernandes, Paula Guedes de Pinho and Nuno G. Oliveira. "MnTnHex-2-PyP5+ Displays Anticancer Features in Non-Small Cell Lung Cancer Cells: Insights from a Multiple Endpoint Study" **Antioxidants** 2022. **IF: 7.675**

## OUR SCIENTIFIC PUBLICATIONS | IBCC

**Cortés J**, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. **N Engl J Med**. 2022 Mar 24;386(12):1143-1154  
I.F.: 91,245

Schmid P, **Cortés J**, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O'Shaughnessy J; KEYNOTE-522 Investigators. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. **N Engl J Med**. 2022 Feb 10;386(6):556-567.  
I.F.: 91,245

Corti C, Antonarelli G, Criscitiello C, Lin NU, Carey LA, **Cortés J**, Poortmans P, Curigliano G. Targeting brain metastases in breast cancer. **Cancer Treat Rev**. 2022 Feb; 103:102324.  
I.F.: 11,143

Monti M, Degenhardt T, Brain E, Wuerstlein R, Argusti A, Puntoni M, Rollandi GA, Corradengo D, Boni L, Ilhan H, Nanni O, **Cortés J**, Piris-Gimenez A, Piccardo A, Iacozzi M, Matteucci F, Di Iorio V, Alberini JL, Schröder C, Harbeck N, Gennari A. ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study. **Front Med (Lausanne)**. 2022 Jan 13; 8:817678.  
I.F.: 4,468

Tarantino P, Corti C, Schmid P, **Cortés J**, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G, André F, Curigliano G. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. **NPJ Breast Cancer**. 2022 Feb 18;8(1):23.  
I.F.: 6,923

Prat A, Guarneri V, Pascual T, Brasó-Maristany F, Sanfeliu E, Paré L, Schettini F, Martínez D, Jares P, Grigoulo G, Dieci MV, **Cortés J**, LLombart Cussac A, Conte B, Marín Aguilera M, Chic N, Puig Butillé J, Martínez A, Galván P, Tsai Y, González -Farré B, Mira A, Vivancos A, Villagrasa P, Parker J, Conte P, Perou C. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early stage HER2- positive breast cancer. Jan 2022  
**EBioMedicine** 75(8):103801.  
I.F.: 8,143



Huang M, Haiderali A, Fox GE, Frederickson A, **Cortes J**, Fasching PA, O'Shaughnessy J. Economic and Humanistic Burden of Triple-Negative Breast Cancer: A Systematic Literature Review. **Pharmacoeconomics**. 2022 May; 40(5):519-558.

I.F.: 4,981

Pérez E, Dang C, Lee C, Singh J, Wang K, Layton J, Gilsenan A, Hackshaw M, **Cortes J**, Perez EA, Dang C, Lee C, Singh J, Wang K, Layton JB, Gilsenan A, Hackshaw MD, Cortes J. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review. **Breast Cancer Res Treat**. 2022 Jul;194(1):1-11.

I.F.: 4,872.

Bruzas S, Gluz O, Harbeck N, Schmid P, **Cortés J**, Blohmer J, Seiberling C, Chiari O, Harrach H, Ataseven B, Shenoy S, Dyson MH, Traut E, Theuerkauf I, Gebauer D, Kuemmel S, Reinisch M. Gene signatures in patients with early breast cancer and relapse despite pathologic complete response. **NPJ Breast Cancer**. 2022 Mar 29;8(1):42.

I.F.: 6,923

González-Martínez S, Pizarro D, Pérez-Mies B, Caniego-Casas T, Rodríguez-Peralto JL, Curigliano G, Cortés A, Gión M, **Cortés J**, Palacios J. Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases. **Cancers (Basel)**. 2022 Feb 23;14(5):1151.

I.F.: 6,102.

Bardia A, **Cortes J**, Hurvitz SA, Delalogue S, Iwata H, Shao ZM, Kanagavel D, Cohen P, Liu Q, Cartot-Cotton S, Pelekanou V, O'Shaughnessy J. AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2-advanced breast cancer. **Ther Adv Med Oncol**. 2022 Mar 15;14:17588359221083956.

I.F.: 8,168

Aran A, Garrigós L, Curigliano G, **Cortés J**, Martí M. Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality? **Cancers (Basel)**. 2022 Mar 31;14(7):1771.

I.F.: 6,102

Sessa C, **Cortes J**, Conte P, Cardoso F, Choueiri T, Dummer R, Lorusso P, Ottmann O, Ryll B, Mok T, Tempero M, Comis S, Oliva C, Peters S, Tabernero J. The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective. **ESMO Open**. 2022 Feb;7(1):100339.

I.F. 4,433

O'Shaughnessy J, Brufsky A, Rugo HS, Tolaney SM, Punie K, Sardesai S, Hamilton E, Loirat D, Traina T, Leon-Ferre R, Hurvitz SA, Kalinsky K, Bardia A, Henry S, Mayer I, Zhu Y, Phan S, **Cortés J**. Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. **Breast Cancer Res Treat**. 2022 Sep;195(2):127-139.

I.F.: 4,872

**Cortés J**, Im SA, Cathcart J. Trastuzumab Deruxtecan for Breast Cancer. Reply. **N Engl J Med**. 2022 Jun 16;386(24):2347.

I.F: 91.245

Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, **Cortés J**, Soria JC, Curigliano G. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. **CA Cancer J Clin**. 2022 Mar;72(2):165-182.

I.F: 508.702

Schmid P, **Cortés J**, Dent R. Pembrolizumab in Early Triple-Negative Breast Cancer. Reply. **N Engl J Med**. 2022 May 5;386(18):1771-1772.

I.F: 91.245

Tarantino P, Corti C, Schmid P, **Cortés J**, Mittendorf EA, Rugo H, Tolaney SM, Bianchini G, André F, Curigliano G. Immunotherapy for early triple negative breast cancer: research agenda for the next decade. **NPJ Breast Cancer**. 2022 Feb 18;8(1):23.

I.F: 6,293

Corti C, Antonarelli G, Valenza C, Nicolò E, Rugo H, **Cortés J**, Harbeck N, Carey LA, Criscitiello C, Curigliano G. Histology-agnostic approvals for antibody-drug conjugates in solid tumours: is the time ripe? **Eur J Cancer**. 2022 Jun 10;171:25-42.

I.F: 9.162

Gion M, Trapani D, Cortés A, Valenza C, Lin N, **Cortés J**, Curigliano G. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. **Am Soc Clin Oncol Educ Book**. 2022 Apr; 42:1-11.

I.F: 6.299

Carey LA, Loirat D, Punie K, Bardia A, Diéras V, Dalenc F, Diamond JR, Fontaine C, Wang G, Rugo HS, Hurvitz SA, Kalinsky K, O'Shaughnessy J, Loibl S, Gianni L, Piccart M, Zhu Y, Delaney R, Phan S, **Cortés J**. Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. **NPJ Breast Cancer**. 2022 Jun 9;8(1):72

I.F: 3,706

Pérez-García JM, Batista MV, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, Garrigós L, Racca F, Servitja S, Blanch S, Gion M, Nave M, Fernández-Abad M, Martínez-Bueno A, Llombart-Cussac A, Sampayo-Cordero M, Malfettone A, **Cortés J**, Braga S. Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial. **Neuro Oncol**. 2022 May 26: noac144.

I.F: 12.3

Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, García Sáenz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, **Cortés J**, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. **J Clin Oncol.** 2022 Oct 1;40(28):3246-3256.

I.F: 44.544

Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim N, Rugo HS, Twelves C, Diéras V, Müller V, Du Y, Currie SL, Hoch U, Tagliaferri M, Hannah AL, **Cortés J**; ATTAIN Investigators. Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial. **JAMA Oncol.** 2022 Jul 1;8(7):1047-1052.

I.F: 31,777.

**Cortés J**, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P; KEYNOTE-355 Investigators. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. **N Engl J Med.** 2022 Jul 21;387(3):217-226.

I.F: 91.245

De Rose F, Meduri B, De Santis MC, Ferro A, Marino L, Colciago RR, Gregucci F, Vanoni V, Apolone G, Di Cosimo S, Delalogue S, **Cortés J**, Curigliano G. Rethinking breast cancer follow-up based on individual risk and recurrence management. **Cancer Treat Rev.** 2022 Sep;109:102434.

I.F: 12.111

Hamilton E, **Cortés J**, Ozyilkan O, Chen SC, Petrakova K, Manikhas A, Jerusalem G, Hegg R, Huober J, Zhang W, Chen Y, Martin M. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR+, HER2- metastatic breast cancer. **Breast Cancer Res Treat.** 2022 Aug;195(1):55-64.

I.F: 4.872

Serra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, Jones GN, Lai Z, Armenia J, Michopoulos F, Llop-Guevara A, Brough R, Gulati A, Pettitt SJ, Bulusu KC, Nikkilä J, Wilson Z, Hughes AM, Wijnhoven PWG, Ahmed A, Bruna A, Gris-Oliver A, Guzman M, Rodriguez O, Grueso J, Arribas J, **Cortés J**, Saura C, Lau A, Critchlow SE, Dougherty B, Caldas C, Mills GB, Barrett JC, Forment JV, Cadogan EB, Lord CJ, Cruz C, Balmaña J, O'Connor MJ. Identification of a molecularly defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance. **Clin Cancer Res.** 2022 Aug 3; CCR-22-0568.

I.F: 12.531

Sánchez-Conde M, Vizcarra P, Pérez-García JM, Gion M, Martialay MP, Taboada J, Alonso-Fernández A, Sampayo-Cordero M, Malfettone A, Tena I, Torre S, Llombart-Cussac A, **Cortés J**. Pembrolizumab in combination with tocilizumab in high-risk hospitalized COVID-19 patients (COPERNICO): A randomized proof-of-concept phase II study. *Int J Infect Dis*. 2022 Aug 17: S1201-9712(22)00475-1.  
I.F: 3.623

Rugo H, Tolaney S, Loirat D, Punie K, Bardia A, Hurvitz S, O'Shaughnessy J, **Cortés J**, Dieras V, Carey L, Gianni L, Piccart M, Loibl S, Goldenberg D, Hong Q, Olivo, Itri ML, Kalinsky K. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer. *NPJ Breast Cancer*. 2022 Aug 29;8(1):98  
I.F: 5.706

Rugo HS, Im SA, Cardoso F, **Cortés J**, Curigliano G, Musolino A, Pegram MD, Bachelot T, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Schwartz GN, Pluard TJ, Ricci F, Gwin WR 3rd, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petráková K, Yardley DA, Freedman O, Jakobsen EH, Gal-Yam EN, Yerushalmi R, Fasching PA, Kaufman PA, Ashley EJ, Perez-Olle R, Hong S, Rosales MK, Gradishar WJ; SOPHIA Study Group. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial. *J Clin Oncol*. 2022 Nov 4:JCO2102937.  
I.F: 44.544

Rugo HS, Bardia A, Marmé F, **Cortés J**, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Pardo PG, Jhaveri KL, Delaney R, Fu O, Lin L, Verret W, Tolaney SM. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. *J Clin Oncol*. 2022 Oct 10;40(29):3365-3376.  
I.F: 44.544

Conforti F, Pala L, Bagnardi V, De Pas T, Colleoni M, Buyse M, Hortobagyi G, Gianni L, Winer E, Loibl S, **Cortés J**, Piccart M, Wolff AC, Viale G, Gelber RD. Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretations. *JAMA Oncol*. 2022 Oct 6.  
I.F: 31.777

Albanell J, Pérez-García JM, Gil-Gil M, Curigliano G, Ruíz Borrego M, Comerma L, Gibert J, Bellet M, Bermejo B, Calvo L, de la Haba J, Espinosa E, Minisini AMM, Quiroga V, Santaballa Bertran A, Mina L, Bellosillo B, Rojo F, Menéndez S, Sampayo-Cordero M, Popa C, Malfettone A, **Cortés J**, Llombart-Cussac A. Palbociclib Rechallenge for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial. *Clin Cancer Res*. 2022 Sep 27:CCR-22-1281. **Shared senior authorship**  
I.F: 12.531

Rugo HS, **Cortes J**, Barrios CH, Cabrera P, Xu B, Huang CS, Kim SB, Melisko M, Nanda R, Pieńkowski T, Rapoport BL, Schwab R. GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer. **Future Oncol.** 2022 Oct 21.

I. F: 3.404

Schettini F, Venturini S, Giuliano M, Lambertini M, Pinato DJ, Onesti CE, De Placido P, Harbeck N, Lüftner D, Denys H, Van Dam P, Arpino G, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen V, Bartsch R, **Cortes J**, Paris I, Martín M, De Placido S, Del Mastro L, Jerusalem G, Curigliano G, Prat A, Generali D. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer. **Cancer Treat Rev.** 2022 Sep 28; 111:102468.

I. F: 12.111

Gion M, Saavedra C, Perez-Garcia J, **Cortes J**. Oligometastatic Disease: When Stage IV Breast Cancer Could Be "Cured". **Cancers (Basel).** 2022 Oct 25;14(21):5229.

I.F: 6.102

Swain SM, Macharia H, **Cortes J**, Dang C, Gianni L, Hurvitz SA, Jackisch C, Schneeweiss A, Slamon D, Valagussa P, du Toit Y, Heinzmann D, Knott A, Song C, Cortazar P. Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis. **Cancers (Basel).** 2022 Oct 15;14(20):5051

.I.F: 6.102

Mouron S, Bueno M.J, Lluch A, Manso L, Calvo I, **Cortes J**, Garcia-Saenz J. A, Gil-Gil M, Martinez-Janez N, Apala J. V, Caleiras E, Ximénez-Embún P, Muñoz J, Gonzalez-Cortijo L, Murillo R, Sánchez-Bayona R, Cejalvo J. M, Gómez-López G, Fustero-Torre C, Sabroso-Lasa S, Malats N, Martinez M, Moreno A, Megias D, Malumbres M, Colomer R, Quintela-Fandino M. Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and Filamin A. **Nat Commun.** 2022 Dec 7;13(1):7529.

López González A, Del Barco Berrón S, Grau I, Galan M, Castelo Fernández B, Cortés A, Sánchez Rovira P, Martínez-Bueno A, Gonzalez X, García A, Gener P, Mina L, Alcalá-López D, Sampayo M, **Cortés J**, Pérez-García JM, Llombart-Cussac A, López-Miranda E. Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study. **Cancers (Basel).** 2022 Nov 29;14(23):5880.

Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, Chiu JWY, Xu B, Hamilton E, Madhusudan S, Iwata H, Altintas S, Henning JW, Curigliano G, Perez-Garcia JM, Kim SB, Petry V, Huang CS, Li W, Frenel JS, Antolin S, Yeo W, Bianchini G, Loi S, Tsurutani J, Egorov A, Liu Y, Cathcart J, Ashfaq S, **Cortés J**. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. **Lancet.** 2022 Dec 6:S0140-6736(22)02420-5.

Loi S, Salgado R, Schmid P, **Cortes J**, Cescon D. W, Winer E. P, Toppmeyer D. L, Rugo H. S, De Laurentiis M, Nanda R, Iwata H, Awada A, Tan A. R, Sun Y, Karantza V, Wang A, Huang L, Saadatpour A, Cristescu R, Yearley J, Lunceford J, Jelinic P, Adams S. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. **J Clin Oncol.** 2022 Dec 16 (en prensa)



**PANGAEA**  
ONCOLOGY



**IOR**

INSTITUTO  
ONCOLÓGICO  
ROSELL



**International  
Breast Cancer  
Center**

